Recent Trends in Cardiovascular Disease and Risk Factors in the Seven Countries: The Netherlands

Smit, Henriëtte A.; Leer, E.M. van; Seidell, Jacob C.; Kromhout, Daan

doi:10.1007/978-4-431-68269-1_11

Cited by 47 publications

(58 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Details have been published elsewhere. 4 Of these Doetinchem subjects, 9336 were also linked to the PHARMO-RLS and of 571 subjects both pharmacy records and genotype data were available for treated hypertensive subjects.…”

Section: Materials and Methods/subjectsmentioning

confidence: 99%

Genetic variation in the renin-angiotensin system modifies the beneficial effects of ACE inhibitors on the risk of diabetes mellitus among hypertensives

et al. 2008

View full text Add to dashboard Cite

The aim of this study was to assess whether the association between angiotensin-converting enzyme (ACE) inhibitor use and the incidence of treated diabetes mellitus is modified by genetic polymorphisms in the renin-angiotensin system (RAS).In a nested case-control study, treated hypertensive patients were genotyped for ACE (insertion (I)/deletion (D)), angiotensinogen (AGT; M235T) and angiotensin II type 1 receptor (AGTR1; A1166C). Cases of newly treated diabetes were identified based on pharmacy records and controls were not yet drug treated for diabetes (case:control ratio 1:10). Self-administered questionnaires and physical examinations were used to assess risk factors for diabetes mellitus. Logistic regression was used to calculate the relative risk of diabetes associated with ACE inhibitor use relative to other antihypertensive treatment, stratified by the RAS genotypes. Among 205 cases and 2050 controls, homozygous 1166A carriers of the AGTR1 gene had a significantly decreased incidence of diabetes associated with current use of ACE inhibitors (odds ratio, OR: 0.47; 95% CI: 0.26-0.84), whereas this incidence was increased among 1166C allele carriers (OR: 1.32; 95% CI: 0.81-2.14). The interaction OR was 3.21 (95% CI: 1.53-6.75). ACE I allele carriers had a significantly reduced incidence of diabetes associated with ACE inhibitors use (OR: 0.63; 95% CI: 0.41-0.98), whereas DD homozygotes had no reduced risk (OR: 0.95; 95% CI: 0.46-1.96). The risk of diabetes associated with ACE inhibitor use was not significantly modified by the AGT-M235T polymorphism. Treatment with ACE inhibitors in hypertensive subjects significantly reduces the occurrence of diabetes in homozygous 1166A carriers of the AGTR1 gene and carriers of the ACE I allele, but not in 1166C allele carriers of the AGTR1 gene and in homozygous ACE D allele carriers.

show abstract

Section: Materials and Methods/subjectsmentioning

confidence: 99%

Genetic variation in the renin-angiotensin system modifies the beneficial effects of ACE inhibitors on the risk of diabetes mellitus among hypertensives

et al. 2008

View full text Add to dashboard Cite

show abstract

“…[24][25][26] Subjects were eligible if they did not use any drugs known to affect energy metabolism, and if they were not on a prescribed or weight loss diet during the previous 2 months. Individuals with a history of diabetes mellitus, diseases affecting the thyroid gland, liver or the gastrointestinal tract were excluded as well as those with glucosuria, anaemia or fasting plasma glucose concentrations 46.9 mmol/l.…”

Section: Subjectsmentioning

confidence: 99%

Fasting leptin and appetite responses induced by a 4-day 65%-energy-restricted diet

et al. 2005

View full text Add to dashboard Cite

Objective: Animal studies show that the leptin decline after acute severe caloric restriction is a peripheral signal to increase food intake. However, most human studies have failed to observe such a relationship. We studied the acute effects of severe caloric restriction on the association between serum leptin concentrations and subjective appetite. Subjects: A total of 44 healthy adult men (aged: 4375 years; BMI: 27.373.2 kg/m 2 ). Measurements: Fasting serum leptin concentrations and self-perceived appetite levels were measured during a 4-day diet containing 36% of the estimated energy requirements. Appetite levels were assessed with a 10-point Likert scale, reflecting hunger, fullness, desire to eat, prospective consumption and total appetite. Results: After the 4-day energy deficit, fasting leptin concentrations decreased by 39.4% (95% CI: À43.6; À34.9%). This decline was associated with an increase in fasting hunger (r ¼ À0.42; Po0.01), desire to eat (r ¼ À0.39; Po0.05) and total appetite (r ¼ À0.38; Po0.05). Furthermore, the association between fasting leptin concentrations and fasting appetite levels became stronger during the energy restriction period (for total appetite: day 0 r ¼ À0.15, P ¼ 0.32; day 2 r ¼ À0.31, P ¼ o0.05; day 4 r ¼ À0.41, Po0.01). Conclusions: The acute proportional reduction in fasting leptin after 4-day energy restriction is associated with an increase in self-perceived appetite. Additionally, the inverse association between proportional fasting leptin concentrations and selfperceived appetite response becomes stronger as energy restriction is prolonged. These findings suggest that leptin has an instrumental role in restoring energy balance in humans through the expression of appetite.

show abstract

“…10 The baseline examination was carried out from 1987 to 1992 in men and women aged 20-59 years, living in Doetinchem, a Dutch town with circa 40 000 inhabitants.…”

Section: Settingmentioning

confidence: 99%

“…The design of this study has been described elsewhere. 10 In addition, blood pressure data was collected from general practitioners from 1987 to 1997.…”

Section: Data Collectionmentioning

confidence: 99%

Interactions between five candidate genes and antihypertensive drug therapy on blood pressure

et al. 2005

View full text Add to dashboard Cite

Despite the availability of effective antihypertensive drugs, there is a large variation in response to these drugs. This study investigates whether polymorphisms in the angiotensin converting enzyme (I/D), angiotensinogen (M235T), a-adducin (G460W), angiotensin II type 1 receptor (1166A/C), or G protein b 3 -subunit (825C/T) gene modify the mean difference in blood pressure levels among diuretics, b-blockers, or ACE-inhibitors users. Data were used from the Doetinchem Cohort Study, and blood pressure data were collected from GPs (1987GPs ( -1997. A marginal generalized linear model (GEE) was used to assess the gene-drug interaction on the mean difference in systolic/diastolic blood pressure. In total, 625 hypertensive individuals were included with a total of 5262 measurements of blood pressure. Only the interaction between diuretic use and the GNB3 825C/T polymorphism was significant (C allele versus TT systolic blood pressure (SBP): 4.33 mmHg [95% CI: 0.14-8.54]). Thus, the mean SBP level among diuretic users may be modified by the GNB3 825C/T polymorphism.

show abstract

Recent Trends in Cardiovascular Disease and Risk Factors in the Seven Countries: The Netherlands

Cited by 47 publications

References 12 publications

Genetic variation in the renin-angiotensin system modifies the beneficial effects of ACE inhibitors on the risk of diabetes mellitus among hypertensives

Genetic variation in the renin-angiotensin system modifies the beneficial effects of ACE inhibitors on the risk of diabetes mellitus among hypertensives

Fasting leptin and appetite responses induced by a 4-day 65%-energy-restricted diet

Interactions between five candidate genes and antihypertensive drug therapy on blood pressure

Contact Info

Product

Resources

About